KZR Stock Analysis
KZ
Uncovered
Kezar Life Sciences Inc is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company which engages in the development of novel small molecule therapeutics to treat autoimmunity and cancer in South San Francisco and California. The company is headquartered in South San Francisco, California and currently employs 84 full-time employees. The company went IPO on 2018-06-21. The firm's product portfolio includes KZR-616 and KZR-261. The KZR-616 is a selective immunoproteasome inhibitor that has completed Phase Ia testing in healthy volunteers and a Phase Ib trial in patients with systemic lupus erythematosus (SLE). KZR-261 is being studied in an open-label Phase I clinical trial designed to evaluate safety and tolerability, pharmacokinetics and pharmacodynamics, as well to explore preliminary anti-tumor activity. The firm has two drug development programs that harness different master regulators of cellular function, which include the immunoproteasome and the Sec61 translocon. The Company’s principal operations are in South San Francisco, California.